Omada Health Q3 2026 earnings

OMDA · 2026-11-05 16:01 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue and membership grew strongly, gross margin expanded, and the company raised its full-year outlook.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$91.3M+34%—Ex. 99.1, income statement
EPS (GAAP)$0.10+$0.16—Ex. 99.1, income statement
EPS (adjusted)$0.18+$0.24—Ex. 99.1, non-GAAP reconciliation
Net income$6.6M+$9.8M—Ex. 99.1, income statement
Adj. EBITDA$12.4M+$10.0M—Ex. 99.1, non-GAAP reconciliation
Adj. EBITDA margin14%+10 pp—Ex. 99.1, non-GAAP reconciliation

Revenue breakdown

SegmentActualYoYShare of revenueNote
Services$85.1M+35%93%Hardware $6.2M
Hardware$6.2M+22%7%—

Margins and costs

  • Gross margin 76% (prior 66%, change +10 pp)
  • Operating expenses $64.5M (+35% YoY)
  • One-offs in the quarter Loss on debt extinguishment $2.1M; Change in fair value of warrant liabilities $0.2M; Provision for credit losses $2.3M (9M)
  • Effective tax rate 0% (prior-year 0%, year-to-date 0%)
  • Non-GAAP bridge Adds back interest, warrant liabilities, debt extinguishment, SBC, amortization, depreciation, loss on disposal

KPIs

MetricActualPrior quarterPrior yearChange
Total Members1.1M—0.81M+36% YoY
Revenue per Member (TTM)$294—$280+5% YoY
Average Member Tenure2 years 4 months—2 years 2 months+10% YoY

Guidance

MetricGuidePrior guideChange
Revenue$344M-$346M$334M-$340M+$10M-$12M
Adjusted EBITDA$32M-$34M$21M-$27M+$11M-$13M

What drove it

  • Revenue story Revenue grew 34% YoY, driven by Services (+35%) and Hardware (+22%).
  • EPS story EPS improved from a loss to a profit, driven by revenue growth, margin expansion, and a tax rate of 0%.
  • One-off check Loss on debt extinguishment $2.1M (Q3 2025) and change in fair value of warrant liabilities $0.2M (Q3 2025) are non-recurring.

The good

  • Revenue grew 34% YoY
  • Total Members increased 36% YoY
  • GAAP gross margin expanded 10 pp to 76%
  • Adjusted EBITDA margin expanded 10 pp to 14%
  • Raised full-year revenue guidance to $344M-$346M

The bad

  • Operating expenses increased 35% YoY
  • Hardware revenue growth (22%) lags Services (35%)

The ugly

  • none

Open questions

  • What is the specific impact of the related party revenue ($19.2M) on the core business metrics?
  • Why is the tax rate 0%?
Full release

Omada Health (OMDA) earnings release, November 5, 2026

Omada Health, Inc. (OMDA) · Form 8-K, Item 2.02 · Filed · SEC filing

Omada Health Reports Third Quarter 2026 Results

• Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million

• Revenue Grew 34% and Total Members Increased 36% Year over Year

• Raises Full Year 2026 Financial Outlook

SAN FRANCISCO - November 5, 2026 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026.

Financial Highlights

• Revenue of $91 million, compared with total revenue of $68 million in Q3 2025

• Gross margin of 76% in the third quarter, up from 66% in Q3 2025

• Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025

• Net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025

• Adjusted EBITDA of $12 million in the third quarter, compared with Adjusted EBITDA of $2 million in Q3 2025

• Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294

• Cash and cash equivalents of $243 million

Please see the non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.

Operational Highlights

• Total Members reached 1.1 million, increasing 36% year over year, reflecting continued demand across Omada Health's integrated cardiometabolic care platform and strong enrollment momentum across diabetes and hypertension programs.

• Average member tenure grew 10% year over year to approximately 2 years and 4 months, which is roughly an additional 2.5 months in program.

“Omada Health delivered its strongest quarter yet, with revenue growing 34% year over year, Total Members increasing 36% and a GAAP gross margin of 76%,” said Sean Duffy, co-founder and CEO of Omada Health. “Our diabetes and hypertension programs led that growth, and average tenure in our programs reached a record of roughly two years and four months. That gives members more time to build lasting habits and the confidence to manage their health.”

Financial Outlook

For the year ending December 31, 2026, Omada Health expects:

• Revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025.

• Adjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025.

We have not provided an outlook for net income (loss) (GAAP) or a reconciliation of expected Adjusted EBITDA to net income (loss) (GAAP) because net income (loss) (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from Adjusted EBITDA, such as loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment.

Conference Call

Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, November 5, 2026, during which management will discuss third quarter 2026 results.

A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.

Those participating via conference call can preregister using the following link: https://register-conf.media-server.com/register/BIcb6fa0e5bd8d4b91a30bc5b4de7e5fb8

About Omada Health

Omada Health (Nasdaq: OMDA) is reverse engineering the way healthcare is delivered in America, putting the space between doctor visits–where health is won or lost–at the center of care. Today's healthcare system poorly serves chronic conditions that require ongoing support outside of the exam room, like obesity, diabetes, hypertension, cholesterol, and musculoskeletal conditions. Omada Health’s virtual-first model combines human-led care teams, connected devices, and AI-enabled technology to deliver personalized care at scale, including support for GLP-1 therapy. Omada Health has served more than two million members since launch across 2,000+ employers, health plans, pharmacy benefit managers, and health systems. Learn more at omadahealth.com.

Financial statements

Income Statement

Three Months Ended September 30, — Includes amounts from a related party of $19.2 million and $18.8 million as of September 30, 2026 and December 31, 2025, respectively.

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue
Services (1)85,10662,936235,392169,392
Hardware (2)6,2005,09421,79714,972
Total revenue91,30668,030257,189184,364
Cost of revenue
Services (3)13,17412,65441,23238,071
Hardware8,85010,30534,19529,016
Total cost of revenue22,02422,95975,42767,087
Gross profit69,28245,071181,762117,277
Operating expenses
Research and development (4)15,27110,30142,59329,131
Sales and marketing (5)29,10722,94385,78265,431
General and administrative (6)20,08414,34049,79937,968
Total operating expenses64,46247,584178,174132,530
Operating income (loss)4,820-2,5133,588-15,253
Other income (expense), net
Interest expense-262-353-294-2,521
Interest income1,9932,0095,5813,414
Loss on debt extinguishment-2,109-2,109
Change in fair value of warrant liabilities-212-1,468
Total other income (expense), net1,731-6655,287-2,684
Income (loss) before provision for income taxes6,551-3,1788,875-17,937
Net income (loss) and comprehensive income (loss)6,551-3,1788,875-17,937
Net income (loss) per share
Basic0.11-0.060.15-0.61
Diluted0.1-0.060.14-0.61
Weighted-average shares outstanding
Basic61,49957,65860,04529,421
Diluted67,12157,65864,56129,421

Income Statement

Three Months Ended September 30,

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Services cost of revenue12133284104
Research and development1,0536112,7841,634
Sales and marketing2,0581,0495,5342,663
General and administrative2,6191,8437,0894,809
Total share-based compensation expense5,8513,53615,6919,210

Income Statement

Three Months Ended September 30, — The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: (in thousands, except percentages)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
GAAP net income (loss) and comprehensive income (loss)6,551-3,1788,875-17,937
Add:
Interest expense2623532942,521
Interest income-1,993-2,009-5,581-3,414
Change in fair value of warrant liabilities2121,468
Loss on debt extinguishment2,1092,109
Share-based compensation expense5,8513,53615,6919,210
Amortization of intangible assets4394391,3171,411
Depreciation and amortization(1)1,2429203,4532,633
Loss on disposal of property and equipment271543
Adjusted EBITDA12,3792,38324,103-1,996
GAAP net income (loss) and comprehensive income (loss) margin (as a percentage of revenue)7-53-10
Adjusted EBITDA margin (as a percentage of revenue)1449-1

Income Statement

Three Months Ended September 30, — (1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs (in thousands, except percentages)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
GAAP gross profit69,28245,071181,762117,277
Add:
Share-based compensation expense12133284104
Amortization of intangible assets4394391,3171,317
Depreciation and amortization(1)1,1388393,1692,366
Non-GAAP gross profit70,98046,382186,532121,064
GAAP gross margin (as a percentage of revenue)76667164
Non-GAAP gross margin (as a percentage of revenue)78687366

Income Statement

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

GAAP Research and development expense15,27110,30142,59329,131
Less:
Share-based compensation expense1,0536112,7841,634
Depreciation and amortization (1)382310361
Non-GAAP research and development expense14,1809,66739,70627,436
Non-GAAP research and development expense (as a % of revenue)16141515
GAAP Sales and marketing expense29,10722,94385,78265,431
Share-based compensation expense2,0581,0495,5342,663
Amortization of intangible assets94
Depreciation and amortization (1)403111287
Non-GAAP sales and marketing expense27,00921,86380,13662,587
Non-GAAP sales and marketing expense (as a % of revenue)30323134
GAAP General and administrative expense20,08414,34049,79937,968

Balance Sheet

September 30, 2026 — press@omadahealth.com

September 30, 2026December 31, 2025
Current assets
Cash and cash equivalents243,151222,036
Accounts receivable, net (1)48,19334,585
Inventory4,8804,486
Deferred commissions, current3,9513,539
Prepaid expenses and other current assets (2)14,8878,288
Total current assets315,062272,934
Property and equipment, net9,7387,942
Deferred commissions, non-current8,9848,711
Intangible assets, net1,0972,414
Goodwill13,24013,240
Other assets417165
Total assets348,538305,406
Current liabilities
Accounts payable (3)8,38510,276
Accrued expenses and other current liabilities (4)41,15940,392
Deferred revenue (5)25,83525,058
Total current liabilities75,37975,726
Total liabilities75,37975,726
Stockholders’ equity
Common stock, $0.001 par value per share; 750,000 and 750,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 61,996 and 58,429 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively6258
Additional paid-in capital720,966686,366
Accumulated deficit-447,869-456,744
Total stockholders’ equity273,159229,680
Total liabilities and stockholders’ equity348,538305,406

Cash Flow

Nine Months Ended September 30,

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Operating activities
Net income (loss)8,875-17,937
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation and amortization4,7704,044
Share-based compensation15,6919,210
Loss on debt extinguishment2,109
Loss on disposal of property and equipment542
Amortization of debt issuance costs285
Non-cash operating lease expense447
Change in fair value of warrant liabilities1,468
Provision for credit losses (1)2,3161,485
Amortization of deferred commissions2,8982,467
Changes in operating assets and liabilities
Accounts receivable (2)-15,924-19,514
Inventory-394148
Prepaid expenses and other current assets (3)-6,599-1,570
Deferred commissions-3,583-2,319
Other non-current assets-252181
Accounts payable (4)-2,0831,373
Operating lease liabilities-415
Accrued expenses and other current liabilities (5)7677,782
Deferred revenue (6)7777,627
Net cash provided by (used in) operating activities7,313-3,127
Investing activities
Purchases of property and equipment-342-1,123
Capitalized internal-use software costs-4,512-3,363
Net cash used in investing activities-4,854-4,486
Financing activities
Proceeds from exercise of stock options19,9845,993
Taxes paid related to net share settlement of equity awards-1,328
Payment of deferred offering costs-4,284
Repayment of debt principal-30,963
Payment of debt extinguishment costs-1,430
Proceeds from initial public offering, net of underwriting discounts and commissions160,532
Net cash provided by financing activities18,656129,848
Net increase in cash and cash equivalents21,115122,235

Cash Flow

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
(unaudited)
Net cash provided by (used in) operating activities7,313-3,127
Purchases of property and equipment-342-1,123
Capitalized internal-use software costs-4,512-3,363
Free Cash Flow2,459-7,613
Other cash flow components:
Net cash used in investing activities-4,854-4,486
Net cash provided by financing activities18,656129,848

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding our ability to deliver profitable growth, business trends, growth prospects and future financial and operating results, and our financial outlook.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the... (truncated) the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; economic uncertainties or downturns in the general economy or the industries in which we or our customers or channel partners operate; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which is being filed at or around the date hereof.

All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update, revise, or correct any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.

Investor Relations Contact:

Craig Gracey ir@omadahealth.com

Media Contact:

Rose Ramseth press@omadahealth.com

(1)

Includes amounts from a related party of $29.0 million and $22.8 million as of September 30, 2026 and December 31, 2025, respectively.

(2)

Includes amounts from a related party of $0.4 million and $0.3 million as of September 30, 2026 and December 31, 2025, respectively.

(3)

Includes amounts from a related party of $1.1 million and $1.0 million as of September 30, 2026 and December 31, 2025, respectively.

(4)

Includes amounts from a related party of $4.2 million and $4.9 million as of September 30, 2026 and December 31, 2025, respectively.

(5)

Includes amounts from a related party of $19.2 million and $18.8 million as of September 30, 2026 and December 31, 2025, respectively.

(1)

Includes amounts from a related party of $53.7 million and $41.8 million for the three months ended September 30, 2026 and 2025, respectively and $151.1 million and $108.2 million for the nine months ended September 30, 2026 and 2025, respectively.

(2)

Includes amounts from a related party of $4.0 million and $3.0 million for the three months ended September 30, 2026 and 2025, respectively and $13.9 million and $9.0 million for the nine months ended September 30, 2026 and 2025, respectively.

(3)

Includes amounts from a related party of $1.4 million and $1.4 million for the three months ended September 30, 2026 and 2025, respectively and $4.1 million and $3.8 million for the nine months ended September 30, 2026 and 2025, respectively.

(4)

Includes amounts from a related party of $0.9 million and $0.6 million for the three months ended September 30, 2026 and 2025, respectively and $2.4 million and $1.6 million for the nine months ended September 30, 2026 and 2025, respectively.

(5)

Includes amounts from a related party of $8.7 million and $7.1 million for the three months ended September 30, 2026 and 2025, respectively and $25.6 million and $19.3 million for the nine months ended September 30, 2026 and 2025, respectively.

(6)

Includes amounts from a related party of $0.4 million and $0.4 million for the three months ended September 30, 2026 and 2025, respectively and $1.4 million and $1.1 million for the nine months ended September 30, 2026 and 2025, respectively.

(1)

Includes changes in related party balances of $1.4 million and $0.5 million for the nine months ended September 30, 2026 and 2025, respectively.

(2)

Includes changes in related party balances of $7.7 million and $15.6 million for the nine months ended September 30, 2026 and 2025, respectively.

(3)

Includes changes in related party balances of less than $0.1 million and $0 for the nine months ended September 30, 2026 and 2025, respectively.

(4)

Includes changes in related party balances of $0.1 million and $0 for the nine months ended September 30, 2026 and 2025, respectively.

(5)

Includes changes in related party balances of $0.7 million and $3.0 million for the nine months ended September 30, 2026 and 2025, respectively.

(6)

Includes changes in related party balances of $0.4 million and $7.1 million for the nine months ended September 30, 2026 and 2025, respectively.

Non-GAAP Financial Measures... (truncated)ch are presented in accordance with GAAP. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, adjusted EBITDA, adjusted EBITDA margin, and free cash flow.

We define non-GAAP gross profit and non-GAAP gross margin as gross profit and gross margin, excluding share-based compensation expense, amortization of intangible assets, and depreciation and amortization.

We define adjusted EBITDA as net income (loss) and comprehensive income (loss) reported on our consolidated statements of operations, excluding the impact of interest expense, interest income, change in fair value of warrant liabilities, loss on debt extinguishment, provision for income taxes, share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment.

Free cash flow is net cash provided by (used in) operating activities less purchases of property and equipment and capitalized internal-use software costs.

We believe these non-GAAP financial measures, when taken collectively with GAAP financial information, are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making. However, there are a number of limitations related to the use of non-GAAP financial measures. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Metric

Total Members:

A member is a person who is enrolled in one of our virtual care programs and that generated a billing event in the preceding 12 months. We believe growth in the number of members is a key indicator of the performance of our business for both investors and management as we monitor the performance of our business, as members primarily drive services revenue. The number of members depends, in part, on our ability to successfully market our services to new customers and channel partners, our ability to sell additional programs to existing customers and channel partners, and our ability to promote awareness of our programs among covered individuals and to encourage their enrollment.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Omada Health earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.